The cancer clinical trials newsletter
Clinical Trials News is a free email digest from the GeneAnalyses team. Each weekday it summarises newly posted and newly updated oncology and life-sciences trials in plain language, and a weekly edition steps back to the trends. Every item links to its ClinicalTrials.gov record, regulator document or primary publication so you can check the design yourself.
Subscribe to Clinical Trials News
A daily, plain-language digest of new oncology and life-sciences clinical trials, with a weekly deep-dive roundup — every update linked to its trial registry or primary source.
Open the newsletterWhat you get
- A daily plain-language brief of new and changed trials, grouped by indication and modality
- A weekly roundup of the readouts, approvals and pipeline shifts that mattered
- Direct links to the trial registry, label or paper behind every claim
- No stock tips, no hype — development activity is not the same as clinical benefit
Recent editions
Full archiveWhat Comes Next When Breast Cancer Survives Initial Treatment?
By the numbers | 10 October 2026 Events tracked: 12 · Dominant indication: Breast cancer / Leukemia (tie), 2 each (16.7% each) · Dominant modality: Checkpoint regimens / Other drug regimens (tie), 4 each (33.3% each) · Largest disclosed funding round: None dis…
Breast Cancer Trial Tests Three Routes After Residual Disease
By the numbers | 10 October 2026 Events tracked: 12 · Dominant indication: Breast cancer / Leukemia (tie), 2 each (16.7% each) · Dominant modality: Checkpoint regimens / Other drug regimens (tie), 4 each (33.3% each) · Largest disclosed funding round: None dis…
A Cancer Drug With a Two-Punch Design Heads to Trial
Here's what happened in cancer research today, in plain English. A small biotech company is about to test a cancer drug built with a new two-part design, and a few bigger drugmakers are testing combinations that could matter for lung, liver, colon and pancreat…
A Second Payload, Aimed at HCC Patients Checkpoints Failed
By the numbers Events covered: 10 · Dominant indication: — · Dominant modality: — · Biggest round: — A Second Payload, Aimed at Liver Cancer's Hardest Patients Acepodia Biotech, Inc. [Dual-payload antibody-drug conjugate | Hepatocellular carcinoma | Phase 1] A…
Breast Cancer Trials Dominate as ADCs Take Center Stage
By the numbers — week ending 5 October 2026 Trial events tracked: 24 · Dominant indication: Breast cancer, 21% share · Dominant modality: Antibody-drug conjugates, 17% share · Phase 3+ readouts: 0 · Total funding: — This was a registration-heavy week rather th…
Two Lab-Made Antibodies Team Up Against Lung Cancer
Here is what happened in cancer research today, in plain English. Most of it is paperwork you will never see: new studies opening their doors to patients. But a few are worth a closer look, including one big bet on a hard-to-treat lung cancer and a couple of s…
A Second DLL3 Bispecific Enters the SCLC Race
By the numbers Events covered: 24 · Dominant indication: — · Dominant modality: — · Biggest round: — Boehringer's DLL3 Combination Challenges Tarlatamab's Head Start Boehringer Ingelheim [Bispecific antibody combination (obrixtamig plus pumitamig) with chemoth…
A New Drug Is About to Challenge Liver Cancer's Old Standard
Here's what happened in cancer research today, in plain English. Most days bring a mix of early experiments and small studies, but today's headline is a genuinely important head-to-head test that could change how doctors treat one of the toughest cancers to ma…
BeOne's HCC challenger takes on two entrenched TKIs
By the numbers Events covered: 21 · Dominant indication: — · Dominant modality: Digital / psychosocial supportive care · Biggest round: — BeOne's BGB-B2033 takes aim at HCC's TKI duopoly BeOne Medicines [Investigational systemic therapy vs. tyrosine kinase inh…
One Drugmaker Is Testing Its New Cancer Combo Against Itself
Here's what happened in cancer research today, in plain English. Researchers around the world posted 25 new cancer clinical trials in the last day, ranging from small studies of nutrition and rehabilitation programs to several large trials of new cancer drugs.…
Junshi Bets Against Its Own Liver Cancer Regimen
By the numbers Events covered: 25 · Dominant indication: — · Dominant modality: Antibody-drug conjugates · Biggest round: — Junshi Puts Its Own Liver Cancer Franchise on the Line Shanghai Junshi Bioscience Co., Ltd. [Combination immunotherapy (bispecific plus…
Doctors May Soon Use a Blood Test to Guide Chemo
Here is what happened in cancer research today, in plain English. Most days bring a mix of early trials, and today is no exception. But one story stands out: a small trial in Spain is testing whether a blood test can tell doctors how hard to fight a cancer tha…
Understand the biology behind the headlines
The digest tells you what changed; these source-linked explainers tell you why the target matters.
Clinical Trials News is an educational research digest, not investment, diagnosis or treatment advice. Early data can change with follow-up and regulatory status can change. Issue list refreshed 15 October 2026.
Read Clinical Trials News on Substack